Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arovella Therapeutics Limited ( (AU:ALA) ) has provided an announcement.
Arovella Therapeutics Limited announced the issuance of 1,617,021 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. This move indicates the company’s compliance with relevant legal provisions and suggests a strategic step in securing capital, potentially impacting its market positioning and stakeholder interests.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company focused on developing invariant natural killer T (iNKT) cell therapy platforms to treat blood cancers and solid tumors. Its lead product, ALA-101, involves CAR19-iNKT cells targeting CD19, an antigen found on various cancer types. The company is also expanding into solid tumor treatment with CLDN18.2-targeting technology and IL-12-TM technology.
Average Trading Volume: 1,287,343
Technical Sentiment Signal: Sell
Current Market Cap: A$113.7M
For detailed information about ALA stock, go to TipRanks’ Stock Analysis page.